|
1
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili
R, Bjarnason GA, et al: Overall survival and updated results for
sunitinib compared with interferon alfa in patients with metastatic
renal cell carcinoma. J Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L,
Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Berger DA, Megwalu II, Vlahiotis A, Radwan
MH, Serrano MF, Humphrey PA, Piccirillo JF and Kibel AS: Impact of
comorbidity on overall survival in patients surgically treated for
renal cell carcinoma. Urology. 72:359–363. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Coebergh JW, Janssen-Heijnen ML, Post PN
and Razenberg PP: Serious co-morbidity among unselected cancer
patients newly diagnosed in the southeastern part of The
Netherlands in 1993–1996. J Clin Epidemiol. 52:1131–1136. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coebergh JW, Janssen-Heijnen ML and
Razenberg PP: Prevalence of co-morbidity in newly diagnosed
patients with cancer: A population-based study. Crit Rev Oncol
Hematol. 27:97–100. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Repetto L, Venturino A, Vercelli M, Gianni
W, Biancardi V, Casella C, Granetto C, Parodi S, Rosso R and
Marigliano V: Performance status and comorbidity in elderly cancer
patients compared with young patients with neoplasia and elderly
patients without neoplastic conditions. Cancer. 82:760–765. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lewis JH, Kilgore ML, Goldman DP, Trimble
EL, Kaplan R, Montello MJ, Housman MG and Escarce JJ: Participation
of patients 65 years of age or older in cancer clinical trials. J
Clin Oncol. 21:1383–1389. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Surbone A: Ethical considerations in
conducting clinical trials for elderly cancer patients. Aging
Health. 4:253–260. 2008. View Article : Google Scholar
|
|
10
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chronic Dis.
40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brunello A, Basso U, Sacco C, Sava T, De
Vivo R, Camerini A, Barile C, Roma A, Maruzzo M, Falci C, et al:
Safety and activity of sunitinib in elderly patients (≥ 70 years)
with metastatic renal cell carcinoma: A multicenter study. Ann
Oncol. 24:336–342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hutson TE, Bukowski RM, Rini BI, Gore ME,
Larkin JM, Figlin RA, Barrios CH, Escudier B, Lin X, Fly K, et al:
Efficacy and safety of sunitinib in elderly patients with
metastatic renal cell carcinoma. Br J Cancer. 110:1125–1132. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gore ME, Szczylik C, Porta C, Bracarda S,
Bjarnason GA, Oudard S, Hariharan S, Lee SH, Haanen J, Castellano
D, et al: Safety and efficacy of sunitinib for metastatic
renal-cell carcinoma: An expanded-access trial. Lancet Oncol.
10:757–763. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kawashima A, Tsujimura A, Takayama H, Arai
Y, Nin M, Tanigawa G, Yasunaga Y, Mukai M, Uemura M, Nakai Y, et
al: Osaka Renal Cell Carcinoma Clinical Study Collaboration:
Importance of continuing therapy and maintaining one-month relative
dose intensity in sunitinib therapy for metastatic renal cell
carcinoma. Med Oncol. 29:3298–3305. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kato R, Kato Y, Matsuura T, Kanehira M,
Takata R and Obara W: Characteristics of early-onset hematotoxicity
of sunitinib in Japanese patients with renal cell carcinoma. BMC
Cancer. 17:2142017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meehan B, Appu S, St Croix B,
Rak-Poznanska K, Klotz L and Rak J: Age-related properties of the
tumour vasculature in renal cell carcinoma. BJU Int. 107:416–424.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yildiz E, Ayan S, Goze F, Gokce G and
Gultekin EY: Relation of microvessel density with microvascular
invasion, metastasis and prognosis in renal cell carcinoma. BJU
Int. 101:758–764. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Denzinger S, Otto W, Burger M,
Hammerschmied C, Junker K, Hartmann A, Wieland WF and Walter B:
Sporadic renal cell carcinoma in young and elderly patients: Are
there different clinicopathological features and disease specific
survival rates? World J Surg Oncol. 5:162007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Verhoest G, Veillard D, Guillé F, De La
Taille A, Salomon L, Abbou CC, Valéri A, Lechevallier E, Descotes
JL, Lang H, et al: Relationship between age at diagnosis and
clinicopathologic features of renal cell carcinoma. Eur Urol.
51:1298–1304; discussion 1304–1305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karakiewicz PI, Jeldres C, Suardi N,
Hutterer GC, Perrotte P, Capitanio U, Ficarra V, Cindolo L, de La
Taille A, Tostain J, et al: Age at diagnosis is a determinant
factor of renal cell carcinoma-specific survival in patients
treated with nephrectomy. Can Urol Assoc J. 2:610–617. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jung EJ, Lee HJ, Kwak C, Ku JH and Moon
KC: Young age is independent prognostic factor for cancer-specific
survival of low-stage clear cell renal cell carcinoma. Urology.
73:137–141. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aapro MS, Köhne CH, Cohen HJ and Extermann
M: Never too old? Age should not be a barrier to enrollment in
cancer clinical trials. Oncologist. 10:198–204. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Akaza H, Naito S, Ueno N, Aoki K, Houzawa
H, Lowenthal Pitman S and Lee SY: Real-world use of sunitinib in
Japanese patients with advanced renal cell carcinoma: Efficacy,
safety and biomarker analyses in 1689 consecutive patients. Jpn J
Clin Oncol. 45:576–583. 2015. View Article : Google Scholar : PubMed/NCBI
|
